Lipoid Pneumonia

Etiology

ELP results from the inhalation or aspiration of various lipid-containing substances. Silent aspiration may occur with mineral oil–based laxatives and nasopharyngeal sprays due to their low viscosity and cough-suppressing properties.[4] Petroleum-based ointments applied around tracheostomy cannulas or endotracheal tubes can aerosolize during airway care, leading to pulmonary deposition.[5] Occupational exposures have been reported in fire-breathing entertainers, automobile mechanics using lubricants, furniture polishers, and metalworkers exposed to cutting oils.[6]

E-cigarettes and vaping products (e-liquids) have recently emerged as significant sources of lipid inhalation. These products often contain lipid-rich components, including vitamin E acetate, medium-chain triglycerides, and flavored propylene glycol or vegetable glycerin mixtures. Certain traditional practices, such as nasal instillation of ghee or sesame oil (an Ayurvedic practice known as nasya), oil pulling, and application of camphorated topical oils, are additional recognized risk factors.[7][8]

EnLP arises as a secondary inflammatory response triggered by the release and accumulation of lipids, typically following tissue injury. Endobronchial obstruction from malignant tumors, benign lesions, or strictures is a common cause. Chronic infections that result in airway scarring, such as posttuberculous stenosis, are also implicated. Autoimmune disorders characterized by granulomatous inflammation, including sarcoidosis and granulomatosis with polyangiitis, may contribute to lipid accumulation.[9] Inherited lipid storage disorders, including Niemann-Pick and Wolman diseases, are other etiologies.[10]

Epidemiology

The true incidence of lipoid pneumonia is unknown. Historical autopsy series have estimated the frequency of this condition at 1% to 2.5%. More than 2,800 confirmed or probable cases were identified during the 2019 US outbreak of e-cigarette or vaping product–associated lung injury (EVALI). Bronchoalveolar lavage (BAL) frequently demonstrated lipid-laden macrophages. Vitamin E acetate was detected in 94% of BAL samples, indicating a likely etiologic role for this substance in vaping-associated cases.[11]

A bimodal distribution is now recognized. The 1st peak occurs in adolescents and young adults exposed to THC and nicotine oils. The 2nd peak occurs in older adults aspirating mineral oil or food-borne lipids due to dysphagia or neurological disease. Geographical variation in incidence appears to reflect the popularity of mineral-oil remedies, traditional cultural practices, and differing national regulations concerning vaping products.[12]

Pathophysiology

The pathophysiology of lipoid pneumonia, whether exogenous or endogenous, involves lipid deposition in the alveoli. Accumulation triggers a persistent inflammatory response.

In ELP, inhaled or aspirated lipid-containing substances bypass normal airway defenses. Silent aspiration or deep inhalation of low-viscosity agents that do not elicit the cough reflex often contributes to alveolar deposition. Once in the alveolar space, long-chain hydrocarbons resist enzymatic degradation and are engulfed by alveolar macrophages, which are unable to metabolize them. This process leads to the formation of vacuolated “foamy” macrophages. Residual lipids are released as these macrophages undergo apoptosis, perpetuating a chronic foreign-body granulomatous reaction characterized by the appearance of multinucleated giant cells, persistent inflammation, surfactant dysfunction, and eventual interstitial fibrosis.

In individuals with chronic aspiration, retained lipids may become encased in granulation tissue, forming a paraffinoma. This well-organized lipogranuloma may radiographically mimic malignancy.

In EnLP, lipid accumulation results from alveolar damage or airway obstruction caused by malignancy, infection, or inflammation. Breakdown of cellular membranes releases cholesterol esters and triglycerides into the alveolar space. Local hypoxia and carbon dioxide retention accelerate lipid deposition and impair clearance. Both forms are characterized by the accumulation of foamy macrophages, ongoing inflammation, and the risk of progression to fibrosis if not identified and managed promptly.[13]

Histopathology

Cytology obtained from BAL or lung biopsy typically demonstrates characteristic findings in lipoid pneumonia. Findings include foamy macrophages with cytoplasmic vacuoles that stain with Oil-Red-O or Sudan black on fresh or frozen sections. Extracellular cholesterol clefts surrounded by foreign-body giant cells are also observed. Although the histopathology of EnLP closely resembles that of ELP, EnLP often exhibits a higher prevalence of intracellular cholesterol clefts. Longstanding disease may show chronic interstitial inflammation and organizing pneumonia.

Routine paraffin embedding dissolves lipid content, rendering it unsuitable for identifying these features. Therefore, frozen-section staining or specialized processing techniques are required for definitive histopathological confirmation.[14]

History and Physical

Nearly half of patients with ELP are asymptomatic.[15] Symptomatic cases are frequently recurrent. Symptom onset in lipoid pneumonia can range from abrupt to insidious, with 2 primary clinical phenotypes recognized. Acute postaspiration inflammation, more common in infants and children, presents with the sudden onset of cough, fever, and dyspnea within hours to days following aspiration. These symptoms are often indistinguishable from those of infectious pneumonia. Chronic, silent microaspirations, typically seen in older adults with dysphagia or neurologic disorders, are characterized by minimal or nonspecific symptoms until incidental imaging reveals abnormalities, or a gradually worsening cough and exertional dyspnea prompt further evaluation.[16] Less common manifestations include fever, night sweats, chest pain, and weight loss.

Physical examination often reveals fine crackles. Wheezing or hemoptysis may occur if bronchial obstruction develops. A thorough and detailed exposure history is essential for accurate diagnosis.

Evaluation

The diagnosis of lipoid pneumonia requires a high index of suspicion. Confirmation necessitates laboratory and radiological evidence. Laboratory evaluation may reveal elevated inflammatory markers, such as C-reactive protein. Arterial blood gas analysis can help assess disease severity. Laboratory findings are generally nonspecific for the condition.

Imaging plays a central role in diagnosis. Chest radiographs often demonstrate bilateral lower-zone or gravity-dependent consolidation. Unilateral, mass-like opacities may also occur, potentially mimicking malignancy or infectious pneumonia.

High-resolution computed tomography provides more definitive diagnostic information. Low-attenuation consolidation or ground-glass opacities with negative Hounsfield units (–30 to –150), indicative of intrapulmonary fat, are observed in approximately 50% to 65% of cases involving mineral oil aspiration. A “crazy-paving” pattern, defined by ground-glass opacity with interlobular and intralobular septal thickening, occurs in approximately 20% of cases. Additional computed tomography findings may include fat-density nodules in a centrilobular distribution (see Image. Lipoid Pneumonia on Chest Computed Tomography).[17] Chronic EnLP may evolve with calcification or cavitation.

Serologic studies, including antinuclear antibodies, rheumatoid factor, and scleroderma antibodies, can help exclude connective tissue diseases. Pulmonary function tests in lipoid pneumonia often demonstrate a reduced diffusing capacity. A restrictive ventilatory pattern may also be observed. These findings are nonspecific and occur in various other pulmonary conditions.

Bronchoscopy is a critical diagnostic tool, supporting the diagnosis of lipoid pneumonia and helping exclude other potential etiologies, such as infectious pneumonia. Identification of lipid-laden macrophages in BAL fluid, stained with Oil-Red-O, supports the diagnosis. This finding is neither highly sensitive nor specific.[18] A lipid-laden macrophage index (LLMI) greater than 50% can distinguish lipoid pneumonia from infectious and other inflammatory lung diseases with high accuracy. Additional tissue sampling via transbronchial or surgical lung biopsy may be required to establish a definitive diagnosis when BAL results are inconclusive or a localized lesion raises concern for malignancy.

Treatment / Management

Management of lipoid pneumonia begins with elimination of the inciting exposure, which remains the cornerstone of therapy. Immediate cessation of e-cigarette or vaping products, substitution of water-soluble lubricants in tracheostomy care, and swallowing evaluation for patients with dysphagia are recommended. Occupational counseling and appropriate respiratory protection are essential for individuals exposed to aerosolized oils in the workplace. 

Supportive care includes maintaining oxygen saturation above 92% with supplemental oxygen as needed. Corticosteroids are widely used based on observational data. A commonly employed regimen consists of prednisone at 0.5 to 1 mg/kg/day for 1 to 2 weeks, followed by a taper over 6 to 8 weeks. Therapy should continue only if demonstrable clinical or radiologic improvement occurs. Empirical antimicrobials should be discontinued once infection is excluded through negative microbiologic testing.[19](B3)

Patients who do not respond to corticosteroids and exposure elimination may be considered for whole-lung or segmental lavage to remove lipid material and inflammatory debris. Lavage should be performed only in centers experienced with procedures similar to those used for pulmonary alveolar proteinosis.[20](B3)

Adjunctive therapies, including intravenous immunoglobulin for immune modulation in immunocompromised pediatric patients and macrolide antibiotics for anti-inflammatory effects in select patients, have been explored. Current evidence is limited to fewer than 10 published cases with inconsistent outcomes.

Differential Diagnosis

The following differential diagnoses should be carefully considered when evaluating a patient for lipoid pneumonia:

• Bacterial, viral, or fungal pneumonia
• Aspiration pneumonia
• Acute respiratory distress syndrome
• Pulmonary alveolar proteinosis
• Acute eosinophilic pneumonia
• Cryptogenic or secondary organizing pneumonia
• Connective tissue disease–associated interstitial lung disease
• Idiopathic interstitial pneumonias
• Lung neoplasm
• Pulmonary hamartoma

Pulmonary hamartoma should be specifically excluded when EnLP presents as a fat-containing pulmonary nodule. Across these conditions, clinical, radiologic, and histopathologic features may overlap with those of lipoid pneumonia. A comprehensive evaluation is therefore essential to establish an accurate diagnosis.

Prognosis

Prognosis in lipoid pneumonia depends on the underlying etiology, timeliness of diagnosis, patient age, and presence of comorbid conditions. Acute vaping-associated ELP often resolves within weeks following exposure cessation and corticosteroid therapy. Chronic aspiration-related disease may progress to fibrosis if not identified and managed promptly.

Complications

Potential complications of lipoid pneumonia include the following:

• Acute or chronic respiratory failure
• Acute respiratory distress syndrome
• Diffuse alveolar hemorrhage
• Secondary infection within lipid-rich consolidations
• Pulmonary hypertension with resultant right heart failure
• Postinfectious bronchiectasis
• Progressive pulmonary fibrosis

Effective prevention requires addressing modifiable risk factors, including cessation of vaping or aspiration-prone practices. Continuous assessment and tailored management reduce the likelihood of long-term outcomes, such as pulmonary fibrosis.